Purpose

In this proposal the investigators will use an accelerated TMS protocol that concentrates the magnetic stimulation that would usually occur over 6 weeks into 10 treatment sessions per days, for 5 consecutive days in patient with treatment-refractory depression. This protocol will build on a previously published study demonstrating clinical efficacy of intermittent theta-burst stimulation (iTBS) on left dorsolateral prefrontal cortex (L-dlPFC) in a treatment refractory population.

Condition

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Gender, inclusive - 18 - 70 years of age - Meets Diagnostic and Statistical Manual of Mental Disorders criteria for primary diagnosis of MDD - Patients must be fluent in English - Participants must have the ability to provide consent - Montgomery Asberg Depression Rating Scale score ≥20 - Failed 2+ prior treatments (treatment-refractory) - May be on current anti-depressant medication at the discretion of PI, if not exceeding doses that would make TMS an increased risk

Exclusion Criteria

  • Pregnancy (Female participants) - MRI contraindication - Medical condition that interferes with the collection or interpretation of MRI data - Implanted devices such as: aneurysm clip or cardiac pacemaker - Diagnosis of stroke, epilepsy, or other neurological disorders interfering with treatment at PI discretion - Any factor the investigator believe may affect participant safety or compliance (ex: ≥100 miles from clinic) - Current alcohol or substance use disorder in last 3 months

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Other
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
Compressed iTBS schedule
Stimulation 3-pulse 50-Hz bursts at 5-Hz for 2-s trains, with trains every 10 s, for 10 minutes, 10 times a day, for 5 consecutive days.
  • Device: intermittent Theta Burst Stimulation
    The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.

Recruiting Locations

More Details

Status
Recruiting
Sponsor
University of Pennsylvania

Study Contact

Walid Makhoul, MD
215 573 2409
walid.makhoul@pennmedicine.upenn.edu

Detailed Description

Major depressive disorder (MDD) is a disabling mental disorder with a lifetime prevalence of up to16% . Approximately 30% of MDD patients suffer treatment resistant depression (TRD), with at least 2 failed adequate trials of pharmacotherapy. Repetitive transcranial magnetic stimulation (rTMS) has been shown to be a safe treatment for TRD, yet the standard clinical technique for using it as treatment depressive disorders is associated with limited efficacy to date. Among the potential causes of limited efficacy have been the scalp based targeting technique that is currently the most common targeting method rather than techniques that incorporate functional magnetic resonance imaging (fMRI) neuronavigation, which have been shown to have greater efficacy. Image guided TMS can target specific functional brain networks with greater resolution that takes into account individual differences in brain anatomy. Another technique for improving treatment efficacy, shown to modulate cortical excitability, may be the application of intermittent theta-burst stimulation in regular intervals, which has been shown to be no different than a longer-in-time application of rTMS. Paired with the evidence that iTBS has produced significant antidepressant responses in severely depressed individuals, and that relapse in depressive states predicts diminished efficacy of treatment as well as increased quantity of TBS pulses to have a beneficial effect, these recent iTBS findings suggest that iTBS may offer a valid treatment alternative to options that have proven otherwise ineffective in treating TRD. Therefore, the investigators aim to administer iTBS to severely-depressed participant in a shorter amount of time, in order to improve their antidepressant outcome. Significance: This protocol builds on different notions: 1. iTBS is not different in treatment outcome than rTMS while applying the same amount of pulses in shorter amount of time; 2. The degree of treatment resistance is indicative of iTBS quantity needed to obtain an antidepressant treatment 3. Repeated iTBS produces a significant effect in treating refractory depression 4. Decreasing the interval between iTBS applications enhanced positive treatment outcomes. Therefore, the compression of iTBS pulses with shorter intervals between sessions is hypothesized to have an increased beneficial effect on individuals affected by treatment-resistant depression.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.